Lack of Efficacy of SGLT2-i in Severe Pneumonia Related to Novel Coronavirus (nCoV) Infection: No Little Help from Our Friends

被引：15

作者：

Bossi, Antonio Carlo ^{[1
]}

Forloni, Franco ^{[1
]}

Colombelli, Paolo Luigi ^{[2
]}

机构：

[1] ASST Bergamo Ovest, Diabet Reg Ctr, Endocrine Unit, Treviglio, BG, Italy

[2] ASST Bergamo Ovest, Internal Med Div, Treviglio, BG, Italy

来源：

DIABETES THERAPY | 2020年 / 11卷 / 07期

关键词：

COVID-19 related pneumonia; SGLT2-inhibitors; Non-diabetic patients;

D O I：

10.1007/s13300-020-00844-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1605 / 1606

页数：2

共 5 条

[1] Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits [J].

Baartscheer, Antonius ;

Schumacher, Cees A. ;

Wust, Rob C. I. ;

Fiolet, Jan W. T. ;

Stienen, Ger J. M. ;

Coronel, Ruben ;

Zuurbier, Coert J. .

DIABETOLOGIA, 2017, 60 (03) :568-573

[2] Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease [J].

Bonnet, F. ;

Scheen, A. J. .

DIABETES & METABOLISM, 2018, 44 (06) :457-464

[3] Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial [J].

Inzucchi, Silvio E. ;

Iliev, Hristo ;

Pfarr, Egon ;

Zinman, Bernard .

DIABETES CARE, 2018, 41 (01) :E4-E5

[4] Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis [J].

Mudaliar, Sunder ;

Alloju, Sindura ;

Henry, Robert R. .

DIABETES CARE, 2016, 39 (07) :1115-1122

[5] SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review [J].

Verma, Subodh ;

McMurray, John J. V. .

DIABETOLOGIA, 2018, 61 (10) :2108-2117

← 1 →